In vitro activity of telithromycin against community acquired respiratory pathogens

被引:0
|
作者
Ulloa, MT
Camponovo, R
Fernández, A
García, P
Prado, V
González, P
Rojas, P
Inostroza, J
Lafourcade, M
Aguilera, L
Porte, L
Cruz, C
Joyas, A
Alcaide, B
Pinto, ME
Giglio, MS
机构
[1] Univ Chile, Programa Microbiol & Micol, ICBM, Fac Med, Santiago, Chile
[2] Catholic Univ Chile, Lab Integramed, Santiago, Chile
[3] Catholic Univ Chile, Hosp Salvador, Santiago, Chile
[4] Catholic Univ Chile, Hosp Clin, Santiago, Chile
[5] Univ Chile, Hosp Clin, Santiago, Chile
关键词
bacterial sensitivity tests; ketolides; respiratory tract infections; telithromycin;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Telithromycin is a new ketolide antimicrobial, that can be useful for the treatment of respiratory infections. Aim: To compare in vitro activity of telithromycin against respiratory pathogens, isolated in outpatient clinics. Materials and methods: Two hundred eighty strains isolated from patients with respiratory infections, were studied, The strains studied were 5 pneumoniae, penicillin sensitive (SPNS:57); intermediate (MG:25) and S aureus meticillin sensitive (SAUS:30). Minimal inhibitory concentration (MIC) by broth microdilution was studied for telitrhomycin and levofloxacin in all strains. Other antimicrobials studied, but not in all strains were erythromycin, clindamycin, trimetoprim sulphamethoxazole, axacillin, amoxicillin-clavulinic acid and cefuroxime. Results: All strains were sensible to telithromycin at a concentration ≤ 4 μ g/ml. MIC 90 and its range for SPNS was 0.03 μ g/ml (≤ 0.004-0.25), for HIN was 2 μ g/ml (0.12-4), for SP was 0.5 μ g/ml (≤ 0.004-2) for MC was 0.5 μ g/ml (0.06-3) and for SAU was 0.25 μ g/ml (0.06-0.25). Conclusions All studied pathogens were sensible to telithromycin in vitro. This antimicrobial is an alternative for the treatment of community acquired respiratory infections.
引用
收藏
页码:419 / 425
页数:7
相关论文
共 50 条
  • [1] Comparative activity of telithromycin against typical community-acquired respiratory pathogens
    Buxbaum, A
    Forsthuber, S
    Graninger, W
    Georgopoulos, A
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (03) : 371 - 374
  • [2] Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens
    Felmingham, D
    Zhanel, G
    Hoban, D
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 : 33 - 42
  • [3] Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections
    Low, DE
    Felmingham, D
    Brown, SD
    Rangaraju, M
    Nusrat, R
    JOURNAL OF INFECTION, 2004, 49 (02) : 115 - 125
  • [4] Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens
    Odenholt, I
    Löwdin, E
    Cars, O
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) : 23 - 29
  • [5] In vitro activity of telithromycin against respiratory tract pathogens in comparison with other antimicrobial agents
    Ling, TKW
    Lee, CC
    CHEMOTHERAPY, 2005, 51 (04) : 182 - 185
  • [6] Activity of telithromycin and other oral antibiotics against respiratory tract pathogens with acquired mechanisms of resistance
    Gómez-Garcés, JL
    Alós, JI
    Hernáiz, C
    Gómez, C
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2004, 22 (06): : 323 - 327
  • [7] In vitro activity of moxifloxacin against community respiratory pathogens in Qatar
    Elshafie, SS
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (03) : 309 - 310
  • [8] Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens
    Drago, L
    De Vecchi, E
    Nicola, L
    Legnani, D
    Gismondo, MR
    APMIS, 2005, 113 (10) : 655 - 663
  • [9] In vitro and in vivo activity of moxifloxacin against community respiratory tract pathogens
    Blondeau, JM
    Felmingham, D
    CLINICAL DRUG INVESTIGATION, 1999, 18 (01) : 57 - 78
  • [10] In Vitro and In Vivo Activity of Moxifloxacin against Community Respiratory Tract Pathogens
    J. M. Blondeau
    D. Felmingham
    Clinical Drug Investigation, 1999, 18 : 57 - 78